Yueming He^*1, Wang Sheng^†1, Weiguo Hu^‡1, Jing Lin^§, Junjun Liu^§, Bing Yu^§, Xinru Mao^§, Lu Zhang^§, Jin Huang^¶, Guangsuo Wang^#

Oncology Research, Vol.27, No.8, pp. 901-910, 2019, DOI:10.3727/096504019X15509372008132

Abstract ROS1 rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting ROS1/MET/ALK rearrangements. Diverse efficacy was observed in ROS1-rearranged NSCLC patients. Because of its rareness, very limited studies have investigated the correlation between different fusion partners and response to crizotinib. In this study, we retrospectively screened 6,235 advanced NSCLC patients (stage IIIB to IV) from five hospitals and identified 106 patients with ROS1 rearrangements based on either plasma or tumor tissue testing using capturebased targeted sequencing. The most frequently occurring fusion partners included cluster of differentiation… More >

Wei Wu^*, Linyan He^†‡, Yan Huang^*, Likun Hou^*, Wei Zhang^*, Liping Zhang^*, Chunyan Wu^*

Oncology Research, Vol.27, No.8, pp. 879-887, 2019, DOI:10.3727/096504018X15451308507747

Abstract An increasing number of studies have demonstrated that microRNAs (miRNAs) may play key roles in various cancer carcinogenesis and progression, including non-small cell lung cancer (NSCLC). However, the expressions, roles, and mechanisms of miR-510 in NSCLC have, up to now, been largely undefined. In vivo assay showed that miR-510 was upregulated in NSCLC tissues compared with that in adjacent nontumor lung tissues. miR-510 expression was significantly correlated with TNM stage and lymph node metastasis. In vitro assay indicated that expressions of miR-510 were also increased in NSCLC cell lines. Downregulation of miR-510 suppressed NSCLC cell proliferation and invasion in vitro.… More >

Xinwen Wang, Fupeng Zhang, Xi Yang, Meiping Xue, Xiaoli Li, Yu Gao, Likun Liu

Oncology Research, Vol.27, No.8, pp. 871-877, 2019, DOI:10.3727/096504018X15426271404407

Abstract Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), afatinib, has been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired resistance to afatinib has not been well studied. In this study, we established afatinib acquired resistant cell lines. Gene array technology was used to screen changes in gene expression between afatinib-resistant lung cancer cells and parental cells. Our results showed that secreted phosphoprotein 1 (SPP1) was significantly increased in afatinib-resistant lung cancer cells. To study the effect of SPP1 on afatinib resistance, siSPP1 was used to knock down SSP1 in afatinib-resistant lung cancer… More >

Hua Zhang^*, Xiuquan He^†, Wenfei Yu^†, Bingqing Yue^†, Ziting Yu^†, Ying Qin^*

Oncology Research, Vol.27, No.8, pp. 859-869, 2019, DOI:10.3727/096504017X15049209129277

Abstract As the noncatalytic subunit of mammalian DNA polymerase, mitotic arrest-deficient protein 2B (MAD2B) has been reported to play a role in cell cycle regulation, DNA damage tolerance, gene expression, and carcinogenesis. Although its expression is known to be associated with poor prognosis in several types of human cancers, the significance of MAD2B expression in lung malignancies is still unclear. Our study showed that MAD2B expression significantly increased in lung cancer, especially in the metastatic tissues. We also found that knockdown of MAD2B inhibited the migration, invasion, and epithelial–mesenchymal transition of lung cancer cells in vitro and the metastasis in vivo,… More >

Jie Wei^*†1, Yuanliang Yan^*†1, Xi Chen^*†, Long Qian^*†, Shuangshuang Zeng^*†, Zhi Li^‡, Shuang Dai^*†, Zhicheng Gong^*†,Zhijie Xu^§

Oncology Research, Vol.27, No.7, pp. 849-858, 2019, DOI:10.3727/096504018X15447833065047

Abstract Over the past decade, natural compounds have been proven to be effective against many human diseases, including cancers. Triptolide (TPL), a diterpenoid triepoxide from the Chinese herb Tripterygium wilfordii Hook F, has exhibited attractive cytotoxic activity on several cancer cells. An increasing number of studies have emphasized the antitumor effects of TPL on non-small cell lung cancer (NSCLC). Here we mainly focused on the key molecular signaling pathways that lead to the inhibitory effects of TPL on human NSCLC, such as mitogen-activated protein kinases (MAPKs) modulation, inhibition of NF- B activation, suppression of miRNA expression, etc. In addition, the effect… More >

Hongliang Yang^*1, Lei Yan^†1, Kai Sun^‡, Xiaodong Sun^†, Xudong Zhang,§ Kerui Cai^†, Tiejun Song^*

Oncology Research, Vol.27, No.3, pp. 359-369, 2019, DOI:10.3727/096504018X15220594629967

Abstract This study aimed to explore the effects of lncRNA BCAR4 on the viability and aggressiveness of non-small cell lung cancer (NSCLC) cells. qRT-PCR was used to determine the expression of BCAR4 and GLI2 downstream genes in NSCLC tissues and cell lines. Chromatin isolation by RNA purification (CHIRP) and Western blot were employed to measure the expression of the GLI2 downstream proteins. Ki-67 expression in nude mice tumors was tested by immunohistochemistry. MTT assay, wound healing assay, and Transwell assay were used to assess NSCLC cell viability and aggressiveness, respectively. Tumor xenograft was conducted to determine the effects of BCAR4 and… More >

Changyu Liu^*, Yongde Liao^*, Sheng Fan^*, Xiangning Fu^*, Jing Xiong^†, Sheng Zhou^†, Man Zou^‡, Jianmiao Wang^§

Oncology Research, Vol.27, No.3, pp. 283-292, 2019, DOI:10.3727/096504017X15035795904677

Abstract G-protein-coupled estrogen receptor (GPER) was found to promote non-small cell lung cancer (NSCLC) by estrogen, indicating the potential necessity of inhibiting GPER by a selective antagonist. This study was performed to elucidate the function of GPER-selective inhibitor G15 in NSCLC development. Cytoplasmic GPER (cGPER) and nuclear GPER (nGPER) were detected by immunohistochemical analysis in NSCLC samples. The relation of GPER and estrogen receptor (ER ) expression and correlation between GPER, ER , and clinical factors were analyzed. The effects of activating GPER and function of G15 were analyzed in the proliferation of A549 and H1793 cell lines and development of… More >

Jing Tang^*1, Xu Yong Li^†1, Jing Bo Liang^‡, De Wu^§, Li Peng^¶, Xiaobing Li^¶

Oncology Research, Vol.27, No.6, pp. 635-641, 2019, DOI:10.3727/096504018X15288447760357

Abstract Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a total of 20 patients with… More >

Jun Shan Ruan^*†, Huan Zhou^*, Lin Yang^‡, Ling Wang^*, Zong Sheng Jiang^§, Hong Sun^*, Shao Ming Wang^*†

Oncology Research, Vol.27, No.5, pp. 593-600, 2019, DOI:10.3727/096504017X15051723858706

Abstract Transforming growth factor- 1 (TGF- 1)-induced epithelial–mesenchymal transition (EMT) of non-small cell lung cancer (NSCLC) may contribute to tumor metastasis. TGF- 1-induced EMT in H1975 cells (a human NSCLC cell line) resulted in the adoption of mesenchymal responses that were predominantly mediated via the TGF- 1–integrin signaling pathway. Ursolic acid has been previously reported to inhibit tumor growth and metastasis in several cancers. However, whether ursolic acid can attenuate TGF- 1-induced EMT in H1975 cells and its underlying mechanisms remain unknown. In this study, ursolic acid significantly attenuated the TGF- 1-induced decrease in E-cadherin level and elevated the level of… More >

Kai Zhang^*, Huajun Chen^†, Ye Wang^‡, Lin Yang^§, Chengzhi Zhou^¶, Weiqiang Yin^#, Guangsuo Wang^§, Xinru Mao^**, Jianxing Xiang^**, Bing Li^**, Tengfei Zhang^**, Shihong Fei^*

Oncology Research, Vol.27, No.5, pp. 575-582, 2019, DOI:10.3727/096504018X15344979253618

Abstract RET rearrangement has been proven as an oncogenic driver in patients with lung cancer. However, the prevalence, clinical characteristics, molecular features, and therapeutic options in RET-rearranged patients remain unclear, especially in Chinese lung cancer patients. We retrospectively collected 6,125 Chinese lung cancer patients who have been profiled using next-generation sequencing (NGS). The clinical demographics and molecular features of RET rearrangement-positive patients were analyzed. RET rearrangements were identified in 84 patients with a proportion of 1.4% in our cohort. The median age at diagnosis was 58 years, and it mainly occurred in females with adenocarcinoma histology. KIF5B-RET was the most frequent… More >